文献速递头颈部肿瘤放疗

局部晚期鼻咽癌CCRT后诱导TPF对比辅助PF的多中心随机III期试验

Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial.
PubMed 文献 · Radiother Oncol · 2026-08-16

该多中心随机III期试验纳入266例局部晚期鼻咽癌患者,比较诱导TPF联合CCRT与CCRT后序贯PF辅助化疗的疗效与安全性。中位随访39个月,两组3年PFS相似(79% vs 74.5%,P=0.454),OS、LRFS、DMFS无显著差异。诱导组CCRT期间恶心呕吐、吞咽、口干等毒性较少,但3-4级白细胞减少和中性粒细胞增多增加。

要点

  • 诱导TPF未改善局部晚期鼻咽癌3年PFS,两组均为79% vs 74.5%(P=0.454)。
  • 诱导组CCRT期间恶心呕吐、吞咽、口干毒性显著减少。
  • 诱导组3-4级白细胞减少和中性粒细胞增多显著增加。

核心结论

  • 在局部晚期鼻咽癌中,诱导TPF未改善3年PFS,且增加血液学毒性,但减少了CCRT期间恶心呕吐、吞咽和口干的发生率。

研究设计与样本

  • 多中心、随机、对照III期临床试验(NCT03574324),2018年5月至2021年7月在中国4家机构招募266例患者,随机分入诱导组(TPF后CCRT)或辅助组(CCRT后PF)。

主要发现

  • 中位随访39个月,3年PFS诱导组79%、辅助组74.5%(P=0.454),OS、LRFS、DMFS无显著差异。
  • 两组放化疗依从率相似。
  • CCRT期间恶心呕吐发生率诱导组101例(77.10%)vs辅助组114例(89.06%)。
  • CCRT期间吞咽毒性诱导组40例(30.53%)vs辅助组56例(43.75%),口干诱导组58例(44.27%)vs辅助组86例(67.19%)。
  • 3-4级白细胞减少诱导组58例(44.27%)vs辅助组28例(21.88%),3-4级中性粒细胞增多诱导组78例(59.54%)vs辅助组24例(18.75%)。

临床怎么用

  • 对于局部晚期鼻咽癌,诱导TPF和辅助PF在生存获益上无显著差异,选择方案时可综合考虑毒性谱差异。
  • 若优先减少CCRT期间恶心呕吐、吞咽困难和口干,可考虑诱导TPF方案,但需警惕血液学毒性增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The efficacy and safety of TPF-induced chemotherapy(IC) combined with concurrent chemoradiotherapy(CCRT) compared to CCRT and sequential PF-adjuvant chemotherapy(AC) lack phase III randomized controlled clinical trials for evaluation, so the comparative efficacy and safety between the two approaches remain unclear. METHODS AND MATERIALS: This randomized clinical phase III trial recruited patients from May 2018 to July 2021,at 4 institutions in China(NCT03574324), 266 patients were enrolled and randomly assigned to either the IC or AC groups. The IC group received TPF followed by CCRT, while the AC group received CCRT followed by PF. We are reporting on the primary outcome of progression-free survival (PFS) and secondary endpoints of overall survival(OS), locoregional relapse-free survival(LRFS), distant metastasis-free survival(DMFS), and toxicity profile. RESULTS: The 3-year PFS was similar between the two groups, with 79 % for the IC group and 74.5 % for the AC group (P = 0.454) at a median follow-up of 39 months. Similar findings were observed, with no significant disparities in OS, LRFS, and DMFS between the two treatment cohorts. Both groups had similar compliance rates for radiotherapy and chemotherapy. However, the IC group experienced fewer grade toxic effects during CCRT, such as nausea/vomiting, swallowing, and dryness (101[77.10 %] vs. 114[89.06 %] patients,40 [30.53 %]vs56 [43.75 %] patients and 58 [44.27 %]vs86 [67.19 %] patients, respectively). However,3-4 grade leukopenia and neutrophilia patients were increased(58 [44.27 %]vs28 [21.88 %] patients and 78 [59.54 %]vs24 [18.75 %]) in the IC group. CONCLUSIONS: In this randomized clinical trial, IC did not improve 3-year PFS for LA-NPC patients and increased hematological toxicity. Still, the advantage of it is that it did reduce the incidence rates of nausea/vomiting, swallowing, and dry mouth during radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. He Q, Li Y, Long J, et al. Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial. Radiother Oncol. 2026. PMID: 42604670. doi:10.1016/j.radonc.2026.111746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。